ArticleProstate international2021
Performance of Ga-68 PSMA PET/CT for diagnosis and grading of local prostate cancer.
Article in Prostate international, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 3 syntheses or guidelines pooled it, 37 citations in OpenAlex.
- A systematic review and meta-analysis to evaluate the diagnostic accuracy of PSMA PET/CT in the initial staging of prostate cancer.Prostate cancer and prostatic diseases · 2025Pooled it
- The diagnostic accuracy of radiolabeled PSMA-ligand PET for tumour staging in newly diagnosed prostate cancer patients compared to histopathology: a systematic review and meta-analysis.European journal of nuclear medicine and molecular imaging · 2023Pooled it
- Radiomics vs radiologist in prostate cancer. Results from a systematic review.World journal of urology · 2023Pooled it
- Recent Advances in Multimodal Assessment Scoring Systems for Prostate Cancer: An Integrated Pathological and Imaging Perspective.Diagnostics (Basel, Switzerland) · 2026Review
- Zirconium-89-based PSMA PET/CT with delayed imaging for early detection of biochemical recurrence in prostate cancer patients with PSA ≤ 0.2 ng/mL: A feasibility study.European journal of nuclear medicine and molecular imaging · 2026Article
- Automated PROMISE V2 Scoring from PSMA PET/CT Reports Using Large Language Models: A Comparative Evaluation of Prompt Design and Model Performance.Current oncology (Toronto, Ont.) · 2026Article
- Practice patterns of Urological Society of Australia and New Zealand urologists regarding pelvic lymph node dissection in prostate cancer surgery.Prostate international · 2026Article
- Machine learning-based construction and validation of an radiomics model for predicting ISUP grading in prostate cancer: a multicenter radiomics study based on [68Ga]Ga-PSMA PET/CT.European journal of nuclear medicine and molecular imaging · 2025Article
- PSMA PET/CT in biochemical recurrence of prostate cancer with PSA levels ≤ 0.2 ng/mL: a German multicenter analysis of conventional PSMA tracers, including [European journal of nuclear medicine and molecular imaging · 2025Article
- Use ofWiener klinische Wochenschrift · 2025Article
- Comparison of mpMRI andDiagnostics (Basel, Switzerland) · 2025Article
- Evaluation of Adrenal Metastases in Prostate Cancer Patients with [68GA]GA-PSMA PET/CT Imaging.Current oncology (Toronto, Ont.) · 2025Article
- Using active surveillance for Gleason 7 (3+4) prostate cancer: A narrative review.Canadian Urological Association journal = Journal de l'Association des urologues du Canada · 2024Review
- Advances in radiology and pathology of prostate cancer: a review for the pathologist.Pathologica · 2024Review
- A Systematic Review on Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA PET) Evaluating Localized Low- to Intermediate-Risk Prostate Cancer: A Tool to Improve Risk Stratification for Active Surveillance?Life (Basel, Switzerland) · 2024Review
- Can the Gleason score be predicted in patients with prostate cancer? A dynamic contrast-enhanced MRI,Diagnostic and interventional radiology (Ankara, Turkey) · 2023Article
- A Systematic Review of the Variability in Performing and Reporting Intraprostatic Prostate-specific Membrane Antigen Positron Emission Tomography in Primary Staging Studies.European urology open science · 2023Article
- Irreversible electroporation for prostate cancer using PSMA PET-CT.Prostate international · 2023Article
- Multiparametric Magnetic Resonance Imaging of the Prostate and Prostate-specific Membrane Positron Emission Tomography Prior to Prostate Biopsy (MP4 Study).European urology open science · 2023Article
- Diagnostic accuracy of F-18-Fluorocholine PET/CT and multiparametric MRI for prostate cancer.Prostate international · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundWe aimed to evaluate the utility of prostate-specific membrane antigen (PSMA) PET/CT for the detection of local disease within the prostate.
methodsThis is a retrospective review of a single-center experience evaluating intraprostatic detection rates compared with final histopathology in a radical prostatectomy (RP) population. Seventy-two patients had PSMA PET/CT scan performed as part of their primary staging. Intraprostatic PSMA PET/CT avidity was assessed. PSMA PET/CT uptake was retrospectively correlated with patient characteristics including final histopathology, MRI Prostate Imaging Reporting and Data System (PI-RADS) score, clinical tumor stage, prostate-specific antigen (PSA) level, and patient age.
resultsThe sensitivity of PSMA PET/CT for the detection of RP-confirmed prostate cancer was 81.2%. Much higher sensitivity was found within certain subpopulations. The patient characteristics that most strongly correlated with focal intraprostatic PSMA PET/CT uptake were patient age (Kendall's tau coefficient τ
conclusionThis trial provides early evidence that PSMA PET/CT assists in the grading of prostate cancer and suggests that the imaging modality is particularly accurate in subpopulations including the elderly and those with palpable disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.